TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30035670

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 90-min training sessions three times/week (n=20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CG) - maintained daily physical activities (n=18)
Number of subjects: 38
Study: 27647856

Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 26084693

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation for 15 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (NDBRJ)
Number of subjects: 14
Study: 24083350

Group type: EXPERIMENTAL
Intervention: Pantoprazole treatment until esophageal mucosal healing
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group (classical healing concept or complete remission concept)
Number of subjects: 626
Study: 21349618

Group type: EXPERIMENTAL
Intervention: Early start of dialysis therapy at a glomerular filtration rate of 10‐14 mL/min/1.73 m(2)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Late start of dialysis therapy at a glomerular filtration rate of 5‐7 mL/min/1.73 m(2)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Early start of dialysis therapy
Number of subjects: 642
Study: 19185645

Group type: EXPERIMENTAL
Intervention: Anacetrapib 10 mg once daily for 8 weeks
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib 40 mg once daily for 8 weeks
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib 150 mg once daily for 8 weeks
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib 300 mg once daily for 8 weeks
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Anacetrapib coadministered with atorvastatin 20 mg
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 16859781

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1065
Study: 14692989

Group type: EXPERIMENTAL
Intervention: Daily visits to supervise diet, exercise, medication, and self-monitoring blood sugar (Group I)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Weekly visits to supervise diet, exercise, medication education, and self-monitoring blood sugar (Group II)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (blood examination only)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group I (Daily visits)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group II (Weekly visits)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study: 11720834

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus ondansetron 8 mg daily (arm B) on days 2-4
Number of subjects: 149

Group type: COMPARATOR
Intervention: Dexamethasone 16 mg i.v. alone (arm A)
Number of subjects: 149
Study: 9494375

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 hours), Clarithromycin (500 mg/12 hours), Amoxycillin (1 g/12 hours) for 12 days
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 hours), Tinidazole (500 mg/12 hours), Clarithromycin (500 mg/12 hours) for 12 days
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 hours), Clarithromycin (500 mg/12 hours), Amoxycillin (1 g/6 hours) for 6 days
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/12 hours), Tinidazole (500 mg/12 hours), Clarithromycin (500 mg/12 hours) for 6 days
Number of subjects: 274
Study: 8243008

Group type: EXPERIMENTAL
Intervention: Effervescent granules during small bowel meal examination
Number of subjects: 0
Study: 3526627

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27527080

Group type: EXPERIMENTAL
Intervention: Vaborbactam (250 to 2,000 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25201533

Group type: EXPERIMENTAL
Intervention: 7.0 mm optic intraocular lens (Eternity X‐70)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 6.0 mm optic intraocular lens (Eternity X‐60)
Number of subjects: 31
Study: 22737877

Group type: EXPERIMENTAL
Intervention: Traditional method tonsillectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-temperature plasma radiofrequency tonsillectomy
Number of subjects: 64
Study: 20531232

Group type: EXPERIMENTAL
Intervention: TNFSF11 gene polymorphisms (rs2200287, rs9525641, rs1054016)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: TNFSF11 gene polymorphisms (rs346578, rs9525641)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: TNFRSF11A gene polymorphism (rs3826620)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: TNFRSF11A gene polymorphism (rs8086340)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Interactions of TNFRSF11A and TNFSF11 polymorphisms with environmental factors
Number of subjects: 306
Study: 18695463

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U weekly for 4 doses in EPO-2 and 3 doses in EPO-3, starting on ICU day 3)
Number of subjects: 2762

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 2762

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2762
Study: 15955241

Group type: EXPERIMENTAL
Intervention: Idiopathic UIP
Number of subjects: 42

Group type: COMPARATOR
Intervention: CVD-associated UIP
Number of subjects: 42

Group type: COMPARATOR
Intervention: Idiopathic NSIP
Number of subjects: 42
Study: 12452219

Group type: EXPERIMENTAL
Intervention: Visual-aided group (photographs plus verbal instructions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (verbal instructions only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual-aided group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 10598520

Group type: EXPERIMENTAL
Intervention: EHF‐puncture
Number of subjects: 222

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 222
Study: 7861487

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostolithotomy alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostolithotomy combined with extracorporeal shock wave lithotripsy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 44
Study: 1508579

Group type: EXPERIMENTAL
Intervention: Immediate splinting
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sonographic surveillance
Number of subjects: 76
Study: 6476586

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine sulfate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.0 mg atropine sulfate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13
Study: 31475623

Group type: EXPERIMENTAL
Intervention: Saffron extract (affron®, 14 mg b.i.d.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30305149

Group type: EXPERIMENTAL
Intervention: Hepatectomy-TACE
Number of subjects: 250

Group type: COMPARATOR
Intervention: Hepatectomy Alone
Number of subjects: 250
Study: 26395350

Group type: EXPERIMENTAL
Intervention: Metal-free double crown retained dentures with Vectris(©)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Electroplated gold copings and metal frameworks (Control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 25054387

Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) epidural injection of methylprednisolone (80 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Parasagittal interlaminar (PIL) epidural injection of methylprednisolone (80 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both TF and PIL groups
Number of subjects: 62
Study: 22036580

Group type: EXPERIMENTAL
Intervention: HVLA manipulation to the lumbosacral joint
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 14
Study: 21114202

Group type: EXPERIMENTAL
Intervention: Generic Pioglitazone (Utmos) 30 mg/day for 24 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Original Pioglitazone (Actos) 30 mg/day for 24 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups (generic and original Pioglitazone)
Number of subjects: 85
Study: 18791976

Group type: EXPERIMENTAL
Intervention: Iron-enriched rice with extruded iron premix rice using ferrous sulfate (ExFeSO4)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Iron-enriched rice with extruded iron premix rice using micronized dispersible ferric pyrophosphate (ExFeP80)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-fortified rice (Control)
Number of subjects: 180
Study: 15795426

Group type: EXPERIMENTAL
Intervention: Carnitine supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss program (hypoenergetic diet, high in protein, low in carbohydrate, increased physical activity)
Number of subjects: 0
Study: 12760312

Group type: EXPERIMENTAL
Intervention: 50 mg EGCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg EGCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg EGCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg EGCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 800 mg EGCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1600 mg EGCG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10550654

Group type: COMPARATOR
Intervention: Anterior cervical fusion (ACF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy (ACD)
Number of subjects: 90
Study: 9514518

Group type: EXPERIMENTAL
Intervention: Continuous muscle stimulation using a completely implantable electrical system
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Continuous muscle stimulation
Number of subjects: 13
Study: 2071201

Group type: EXPERIMENTAL
Intervention: Functional plaster brace applied immediately after reduction of the fracture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Colles' plaster (control group)
Number of subjects: 60
Study: 6400701

Group type: EXPERIMENTAL
Intervention: Breakfast containing banana
Number of subjects: 8

Group type: COMPARATOR
Intervention: Breakfast containing orange juice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Other breakfasts (not specified)
Number of subjects: 8
Study: 30903796

Group type: EXPERIMENTAL
Intervention: Oral semaglutide, 7 mg/d
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Oral semaglutide, 14 mg/d
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Oral semaglutide, 3 mg/d
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Sitagliptin, 100 mg
Number of subjects: 1864
Study: 27768242

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Apremilast (after switching from placebo)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Etanercept (after switching to apremilast)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Apremilast (continuing from apremilast)
Number of subjects: 250
Study: 23846523

Group type: EXPERIMENTAL
Intervention: Lubiprostone plus PEG
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo plus PEG
Number of subjects: 123
Study: 25372920

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 22325065

Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) intervention, involving up to 10 sessions over 4 months with licensed social workers.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list control group (received BTB 4 months later).
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) intervention.
Number of subjects: 208
Study: 19429875

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (Standard Glucose Monitoring)
Number of subjects: 129
Study: 18158694

Group type: EXPERIMENTAL
Intervention: Ankle stabilizing orthosis
Number of subjects: 11

Group type: COMPARATOR
Intervention: No ankle stabilizing orthosis (control)
Number of subjects: 11
Study: 15230341

Group type: EXPERIMENTAL
Intervention: Cefaclor extended release 500‐mg tablet after low‐fat vegetarian diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefaclor extended release 500‐mg tablet after high‐fat non-vegetarian diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefaclor extended release 500‐mg tablet after high‐fat vegetarian diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefaclor extended release 500‐mg tablet after overnight fasting
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefaclor extended release 500‐mg tablet after rice diet
Number of subjects: 23
Study: 11959049

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9859117

Group type: EXPERIMENTAL
Intervention: Acupuncture at specific points (verum group, n = 22)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acupuncture at non-specific locations (placebo group, n = 24)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Only pharmacological treatment (control group, n = 24)
Number of subjects: 70
Study: 8706110

Group type: EXPERIMENTAL
Intervention: Familial hemiplegic migraine patients
Number of subjects: 83

Group type: COMPARATOR
Intervention: Migraine with aura control group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Migraine without aura control group
Number of subjects: 83
Study: 1933356

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 mg i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control placebo)
Number of subjects: 0
Study: 7033916

Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with female voice
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with male voice
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with musical background
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with environmental background
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Relaxation training tapes (both male and female voices)
Number of subjects: 76
Study: 30817628

Group type: EXPERIMENTAL
Intervention: MOVI-daFIT! intervention (HIIT program)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (regular physical education sessions)
Number of subjects: 10
Study: 29046301

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d, 2000 IU/d, or 4000 IU/d)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Vitamin D inadequacy (serum 25-hydroxyvitamin D concentration <50 nmol/L)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baseline obesity (BMI ≥30)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Racial/Ethnic differences
Number of subjects: 301
Study: 25431239

Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin FDC 10/20 mg
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin FDC 10/40 mg
Number of subjects: 633
Study: 24398143

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 240
Study: 21712713

Group type: EXPERIMENTAL
Intervention: Microneedles for lidocaine injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hypodermic needles for lidocaine injection (control)
Number of subjects: 15
Study: 19365287

Group type: EXPERIMENTAL
Intervention: Participatory intervention for workplace improvement
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study: 17521544

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous mononuclear bone marrow cells (Group I; n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Systemic administration of granulocyte colony-stimulating factor (G-CSF) (Group II; n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group III; n=10)
Number of subjects: 30
Study: 14725484

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: HES 200/0.5 (6%)
Number of subjects: 52
Study: 12031746

Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 9694705

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) in combination with daunorubicin and cytarabine (DA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine (DA) only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA)
Number of subjects: 20
Study: 8124802

Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High sodium diet (350 mmol/d)
Number of subjects: 36
Study: 2505485

Group type: EXPERIMENTAL
Intervention: 3% acyclovir ophthalmic ointment
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2% trifluorothymidine (TFT) ophthalmic ointment
Number of subjects: 50
Study: 371690

Group type: EXPERIMENTAL
Intervention: Domperidone (16 mg, injected 1 hour before cytostatic therapy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14
Study: 31566680

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus endocrine therapy
Number of subjects: 1389
Study: 30528218

Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose of 2000 mg per day)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 514
Study: 28416199

Group type: EXPERIMENTAL
Intervention: Patients with heart failure (HF)
Number of subjects: 10135

Group type: EXPERIMENTAL
Intervention: Patients with LVEF ≤40%
Number of subjects: 10135

Group type: COMPARATOR
Intervention: Patients without heart failure (HF)
Number of subjects: 10135
Study: 25533574

Group type: EXPERIMENTAL
Intervention: TCST program (12 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 81
Study: 24021604

Group type: EXPERIMENTAL
Intervention: Complementary physical treatment method to stimulate arteriolar vasomotion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20971747

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study: 19713130

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Laparoscopic bilateral occlusion of uterine arteries
Number of subjects: 66
Study: 17227688

Group type: EXPERIMENTAL
Intervention: High-potency zoster vaccine (approximately 207,000 plaque-forming units/dose)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Low-potency zoster vaccine (approximately 58,000 plaque-forming units/dose)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: High-potency zoster vaccine
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Low-potency zoster vaccine
Number of subjects: 698
Study: 15121488

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11304900

Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 14
Study: 9207599

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin beta, Puregon)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Urinary gonadotropins (hMG or urinary FSH)
Number of subjects: 1160
Study: 8250683

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 39
Study: 3117403

Group type: EXPERIMENTAL
Intervention: Short-term intravesical chemotherapy (ADM 30 mg/30 ml, ADM 20 mg/40 ml, MMC 20 mg/40 ml) administered twice a week for 4 weeks after TUR
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Long-term intravesical chemotherapy (ADM 30 mg/30 ml, ADM 20 mg/40 ml, MMC 20 mg/40 ml) administered twice a week for 1 week, every 2 weeks for 7 weeks, monthly for 8 months, and finally once every 3 months for 1 year
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 1182
Study: 31725060

Group type: EXPERIMENTAL
Intervention: MCH‐ART arm (integrated maternal and child health services)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Standard of care arm (immediate transfer to general ART services)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: MCH‐ART arm
Number of subjects: 471

Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 471
Study: 29424469

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP < 120 mm Hg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP < 140 mm Hg)
Number of subjects: 1000
Study: 27776530

Group type: EXPERIMENTAL
Intervention: Surgical CryoMaze followed by catheter ablation 3 months post-surgery
Number of subjects: 260

Group type: COMPARATOR
Intervention: Surgical CryoMaze alone
Number of subjects: 260
Study: 24033306

Group type: EXPERIMENTAL
Intervention: Meditation practice for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study: 24187870

Group type: EXPERIMENTAL
Intervention: Sini injection (SG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Model group (MG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal group (NG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham operation group (OG)
Number of subjects: 102